Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma

MT Newswires Live

09/18

Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.

The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.

Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.

The company's shares fell 38% in recent trading Thursday.

Price: 3.54, Change: -2.17, Percent Change: -38.00

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568403375"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568403375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568403375?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568403375","market":"sh","top_or_hot":-1,"title":"Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma","media":"MT Newswires Live","content":"<html><body><p> Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.</p><p>The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.</p><p>Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.</p><p>The company's shares fell 38% in recent trading Thursday.</p><p>Price: 3.54, Change: -2.17, Percent Change: -38.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune Says Path Forward Not Determined for RP1 in Advanced Melanoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-18 21:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.</p><p>The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.</p><p>Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.</p><p>The company's shares fell 38% in recent trading Thursday.</p><p>Price: 3.54, Change: -2.17, Percent Change: -38.00</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FORD","symbol_name":"福沃德工業","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568403375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568403375","pubTimestamp":1758203860,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Replimune  said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.The company's shares fell 38% in recent trading Thursday.Price: 3.54, Change: -2.17, Percent Change: -38.00","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FORD":"福沃德工业","BK4145":"电子制造服务","REPL":"Replimune Group Inc.","BK4202":"服装、服饰与奢侈品","BK4139":"生物科技"},"translate_title":"Replimune表示晚期黑色素瘤中RP1的前进道路尚未确定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FORD":1.5,"REPL":1},"content_text":"Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.The company's shares fell 38% in recent trading Thursday.Price: 3.54, Change: -2.17, Percent Change: -38.00","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}